Basel-based Novartis sees cell and gene therapies eventually contributing about 15% of its revenue.[nL8N2874FU][nL5N25V4JJ] T cells currently harvested from Europeans getting the $400,000-per-patient Kymriah blood cancer therapy must now be sent to a U.S. laboratory for re-engineering. Analysts have called the lack of manufacturing capacity a "major bottleneck". Novartis is investing some $500 million in new facilities around the world to address production bottlenecks and drug companies including Novartis, Pfizer and others, have plans to spend $2 billion building out gene and cell therapy manufacturing after rapid expansion into these treatments. Kymriah's global rollout in 20 countries, plus Novartis's efforts to expand the therapy's indications, make adding commercial production a priority, including in China and Japan. [nL8N1WD64W] Kymriah's 2018 approval was hailed as a breakthrough as a last-ditch treatment for acute lymphoblastic leukemia and diffuse large B-cell lymphoma.